van den Berg HM - Search Results

1

Factor VIII-specific memory B cells in patients with hemophilia A.

van Helden PM, Kaijen PH, Fijnvandraat K, van den Berg HM, Voorberg J. van Helden PM, et al. Among authors: van den berg hm. J Thromb Haemost. 2007 Nov;5(11):2306-8. doi: 10.1111/j.1538-7836.2007.02736.x. J Thromb Haemost. 2007. PMID: 17958750 Free article. No abstract available.

2

Inhibitor development in a multitransfused patient with severe haemophilia A.

van den Berg HM, Roosendaal G, Voorberg J, Mauser-Bunschoten EP. van den Berg HM, et al. Thromb Haemost. 1999 Jul;82(1):151-2. Thromb Haemost. 1999. PMID: 10456472 No abstract available.

3

Domain specificity of factor VIII inhibitors during immune tolerance induction in patients with haemophilia A.

van Helden PM, Kaijen PH, Mauser-Bunschoten EP, Fischer K, van den Berg HM, Voorberg J. van Helden PM, et al. Among authors: van den berg hm. Haemophilia. 2010 Nov;16(6):892-901. doi: 10.1111/j.1365-2516.2010.02272.x. Haemophilia. 2010. PMID: 20491952

4

Discordant antibody response in monozygotic twins with severe haemophilia A caused by intensive treatment.

Gouw SC, ter Avest PC, van Helden PM, Voorberg J, van den Berg HM. Gouw SC, et al. Among authors: van helden pm, van den berg hm. Haemophilia. 2009 May;15(3):712-7. doi: 10.1111/j.1365-2516.2009.01998.x. Haemophilia. 2009. PMID: 19432924

5

Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.

Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briët E, van den Berg HM. Mauser-Bunschoten EP, et al. Among authors: van den berg hm. Thromb Haemost. 1994 Jun;71(6):703-6. Thromb Haemost. 1994. PMID: 7974335 Free article. Clinical Trial.

6

Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A.

Gouw SC, van den Berg HM, le Cessie S, van der Bom JG. Gouw SC, et al. Among authors: van den berg hm, van der bom jg. J Thromb Haemost. 2007 Jul;5(7):1383-90. doi: 10.1111/j.1538-7836.2007.02595.x. Epub 2007 Apr 20. J Thromb Haemost. 2007. PMID: 17456190 Free article.

7

Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice.

ter Avest PC, Fischer K, Mancuso ME, Santagostino E, Yuste VJ, van den Berg HM, van der Bom JG; CANAL Study Group. ter Avest PC, et al. Among authors: van den berg hm, van der bom jg. J Thromb Haemost. 2008 Dec;6(12):2048-54. doi: 10.1111/j.1538-7836.2008.03187.x. Epub 2008 Oct 7. J Thromb Haemost. 2008. PMID: 18983511 Free article.

8

The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A.

Vlot AJ, Mauser-Bunschoten EP, Zarkova AG, Haan E, Kruitwagen CL, Sixma JJ, van den Berg HM. Vlot AJ, et al. Among authors: van den berg hm. Thromb Haemost. 2000 Jan;83(1):65-9. Thromb Haemost. 2000. PMID: 10669157

9

Clinical prediction models for inhibitor development in severe hemophilia A.

van den Berg HM, Chalmers EA. van den Berg HM, et al. J Thromb Haemost. 2009 Jul;7 Suppl 1:98-102. doi: 10.1111/j.1538-7836.2009.03437.x. J Thromb Haemost. 2009. PMID: 19630778 Free article.

10

Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis.

van Dijk K, van der Bom JG, Fischer K, de Groot PG, van den Berg HM. van Dijk K, et al. Among authors: van den berg hm, van der bom jg. J Thromb Haemost. 2007 May;5(5):1062-4. doi: 10.1111/j.1538-7836.2007.02447.x. Epub 2007 Feb 14. J Thromb Haemost. 2007. PMID: 17388802 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

251 results

Search Page